Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
Cancer Letters,  Clinical Article

Reckamp KL – With the approval of the antiangiogenic antibody bevacizumab in non–small cell lung cancer (NSCLC) and other malignancies, the tumor vasculature has emerged as a worthwhile therapeutic target. Second–line therapies have the potential to improve overall survival and quality of life over best supportive care alone.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Nursing

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Nursing Articles

Indexed Journals in Nursing: Journal of Advanced Nursing, Journal of Clinical Nursing, Nurse Education In Practicemore